Skip to content

Geron GERN EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Incyte logo
IncyteINCY
$1.47+83.7%
Immunome logo
ImmunomeIMNM
-$0.48+7.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$0.48+51.0%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$1.02+10.5%
Celcuity logo
CelcuityCELC
-$0.97-12.8%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's EPS (diluted)?
Geron (GERN) reported EPS (diluted) of -$0.01 in Q1 2026.
How has Geron's EPS (diluted) changed year-over-year?
Geron's EPS (diluted) increased by 66.7% year-over-year, from -$0.03 to -$0.01.
What is the long-term trend for Geron's EPS (diluted)?
Over 4 years (2021 to 2025), Geron's EPS (diluted) has grown at a -21.9% compound annual growth rate (CAGR), from -$0.35 to -$0.13.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.